Because we had observed that the MAPK pathway regulates IFI6, we tested whether pharmacological MEK inhibitors could be combined with DNA replication stress-inducing drugs to treat NRAS-mutant melanoma. The gene discussed is MAP2K7; the disease is melanoma.